Log in Register

Login to your account

Username *
Password *
Remember Me

Create an account

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
+38 (067) 233-75-91

U.S. created a new class of protein for the treatment of cancer and even more

U.S. created a new class of protein for the treatment of cancer and even more
Experts from the University of Georgia have created a protein that triggers the death receptor associated with a number of diseases, including cancer. The discovery could pave the way for new therapeutic directions.


Action ProAgio protein is directed to communicate with the integrin αVβ3 - a cell receptor, abnormal expression of which is accompanied by the emergence and development of pathological changes in the body. Tests have shown that accumulates ProAgio caspase-8, an enzyme involved in programmed cell death, in the cytoplasm αVβ3. Thus, local protein activates apoptosis integrin stripping medium.
Tests on mice have shown that using ProAgio significantly slows down the speed of cancer flowing, particularly tumors of the blood vessels. When this protein prevents the development of the disease without affecting the blood vessels themselves. Analysis of the level of toxicity is also confirmed that ProAgio harmless to organs health and tissues of animals.
"We have formed a great triangle. We've developed a protein which binds to another cell site, the program immediately starts its destruction. And the death of abnormal cells allows us to kill the disease, "- research's lead author Ji-Ren Liu said.

The role of integrin αVβ3 for provoking a broad spectrum of diseases has been studied before. The traditional approach is to try to link it to a ligand - a chemical compound intended for targeted initiate molecular processes that do not work. The work of American scientists has provided the scientific community alternative technology impact on the well-known enzyme.


We use cookies to support your experience on our site. By continuing to use our site you agree to our use of cookies.